Voyager Therapeutics (NASDAQ:VYGR) was downgraded by equities researchers at BidaskClub from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Monday, BidAskClub reports.
A number of other equities research analysts also recently weighed in on the stock. Chardan Capital reiterated a “hold” rating and set a $15.00 price target on shares of Voyager Therapeutics in a research note on Friday, August 14th. Wedbush decreased their price objective on Voyager Therapeutics from $24.00 to $19.00 and set an “outperform” rating on the stock in a report on Tuesday, October 13th. HC Wainwright dropped their price objective on Voyager Therapeutics from $18.00 to $14.00 and set a “buy” rating for the company in a research note on Tuesday, August 4th. Finally, Zacks Investment Research lowered shares of Voyager Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, October 16th. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and eight have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $16.80.
Shares of NASDAQ VYGR traded up $0.01 during mid-day trading on Monday, hitting $11.03. The company had a trading volume of 173,789 shares, compared to its average volume of 314,158. Voyager Therapeutics has a 12 month low of $6.26 and a 12 month high of $16.53. The firm has a market cap of $412.86 million, a P/E ratio of -6.73 and a beta of 1.80. The business’s 50-day simple moving average is $11.20 and its 200-day simple moving average is $11.71.
Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.23) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.75) by $0.52. Voyager Therapeutics had a negative return on equity of 66.46% and a negative net margin of 60.61%. The company had revenue of $28.68 million during the quarter, compared to the consensus estimate of $16.19 million. Analysts anticipate that Voyager Therapeutics will post -1.84 EPS for the current fiscal year.
Hedge funds and other institutional investors have recently modified their holdings of the company. Bank of New York Mellon Corp boosted its holdings in Voyager Therapeutics by 25.0% during the second quarter. Bank of New York Mellon Corp now owns 1,122,435 shares of the company’s stock worth $14,165,000 after buying an additional 224,246 shares during the last quarter. Clearbridge Investments LLC boosted its holdings in Voyager Therapeutics by 19.4% in the 1st quarter. Clearbridge Investments LLC now owns 1,208,675 shares of the company’s stock valued at $11,059,000 after purchasing an additional 196,342 shares during the period. Assenagon Asset Management S.A. acquired a new position in shares of Voyager Therapeutics during the 3rd quarter worth approximately $1,498,000. Bank of Montreal Can increased its holdings in shares of Voyager Therapeutics by 56.6% during the second quarter. Bank of Montreal Can now owns 256,410 shares of the company’s stock worth $3,419,000 after purchasing an additional 92,645 shares during the period. Finally, Wells Fargo & Company MN increased its holdings in shares of Voyager Therapeutics by 17.8% during the first quarter. Wells Fargo & Company MN now owns 457,906 shares of the company’s stock worth $4,191,000 after purchasing an additional 69,335 shares during the period. 78.79% of the stock is currently owned by institutional investors.
Voyager Therapeutics Company Profile
Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease.
Further Reading: How is an ETF different from a mutual fund?
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.